FAQ: Quantumzyme's AI-Driven Enzyme Engineering Platform Expansion for Green API Manufacturing

What is Quantumzyme announcing in this content?

Quantumzyme is expanding its proprietary AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients (APIs) beyond ibuprofen, marking a major milestone in advancing green pharmaceutical manufacturing.

Why is this expansion significant for the pharmaceutical industry?

This expansion addresses the environmental impact of traditional API manufacturing by reducing hazardous waste, toxic solvent use, and carbon emissions at scale, while supporting domestic manufacturing and supply chain resilience goals.

How does Quantumzyme’s enzyme engineering platform work?

The platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts that replace traditional energy-intensive chemical reaction steps.

What specific APIs are included in the expanded R&D pipeline?

The expanded pipeline includes multiple high-volume APIs, including chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely used in the global generics sector.

What are the key benefits of Quantumzyme’s biocatalysis-first approach?

The approach offers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency compared to traditional manufacturing methods.

Who is leading Quantumzyme and what is their vision?

Naveen Kulkarni, CEO of Quantumzyme, stated their vision is to ‘redefine chemical manufacturing through sustainable innovation’ and advance greener chemistry while supporting supply chain resiliency.

When was this announcement made and what is the company’s stock symbol?

The announcement was made on November 11, 2025, and Quantumzyme trades on the OTCQB market under the symbol QTZM.

How does this expansion support broader sustainability and supply chain goals?

The platform supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals by providing a sustainable alternative to overseas manufacturing using legacy chemistries.

What is Quantumzyme’s background and expertise?

Quantumzyme Corp. is a pioneering biotransformation company that specializes in green chemistry, harnessing quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts.

Where can I find more information about Quantumzyme?

For more information and updates, visit www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.